NASDAQ:TCDA - Tricida Stock Price, News, & Analysis

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida Inc (NASDAQ:TCDA) released its quarterly earnings results on Thursday, November, 8th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.84) by $0.19. View Tricida's Earnings History.

Tricida is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Tricida.

3 Wall Street analysts have issued 12-month price objectives for Tricida's shares. Their predictions range from $32.00 to $50.00. On average, they anticipate Tricida's share price to reach $38.6667 in the next year. This suggests a possible upside of 76.1% from the stock's current price. View Analyst Price Targets for Tricida.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tricida.

Media coverage about TCDA stock has been trending very positive on Monday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tricida earned a news impact score of 3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Tricida saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,827,972 shares, an increase of 64.2% from the December 14th total of 1,113,350 shares. Based on an average daily trading volume, of 296,733 shares, the days-to-cover ratio is currently 6.2 days. Currently, 6.7% of the company's stock are short sold. View Tricida's Current Options Chain.

Some companies that are related to Tricida include Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Agios Pharmaceuticals (AGIO), Emergent Biosolutions (EBS), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Akcea Therapeutics (AKCA), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD) and Reata Pharmaceuticals (RETA).

(TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

Tricida's lock-up period expired on Tuesday, December 25th. Tricida had issued 11,700,000 shares in its initial public offering on June 28th. The total size of the offering was $222,300,000 based on an initial share price of $19.00. Since the end of Tricida's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $21.96.

Tricida has a market capitalization of $924.66 million. Tricida employs 61 workers across the globe.

The official website for Tricida is http://www.tricida.com.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]